Crossmark

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial

Crossref DOI link: https://doi.org/10.1038/s41598-017-11048-9

Published Online: 2017-09-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Passardi, Alessandro

Scarpi, Emanuela

Gelsomino, Fabio

Palladino, Maria Angela

Casadei Gardini, Andrea https://orcid.org/0000-0001-6289-7202
Turci, Daniele

Chiuri, Vincenzo Emanuele

Mucciarini, Claudia

Tassinari, Davide

Ragazzini, Angela

Frassineti, Giovanni Luca

Valgiusti, Martina

Ulivi, Paola

Amadori, Dino
License Information

Text and Data Mining valid from 2017-09-05

Version of Record valid from 2017-09-05
More Information

Article History

Received: 30 March 2017

Accepted: 18 August 2017

First Online: 5 September 2017

Competing Interests

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below